Biomea Fusion Inc
Company Profile
Business description
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Contact
900 Middlefield Road
4th Floor
Redwood CityCA94063
USAT: +1 650 980-9099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
106
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,385.50 | 16.20 | 0.19% |
| CAC 40 | 7,696.92 | 31.01 | -0.40% |
| DAX 40 | 23,249.65 | 94.89 | -0.41% |
| Dow JONES (US) | 40,829.00 | 389.83 | -0.95% |
| FTSE 100 | 8,597.42 | 1.07 | 0.01% |
| HKSE | 23,054.76 | 392.05 | 1.73% |
| NASDAQ | 17,689.66 | 154.58 | -0.87% |
| Nikkei 225 | 36,777.88 | 52.81 | -0.14% |
| NZX 50 Index | 12,459.77 | 38.68 | 0.31% |
| S&P 500 | 5,606.91 | 43.47 | -0.77% |
| S&P/ASX 200 | 8,166.70 | 15.30 | 0.19% |
| SSE Composite Index | 3,335.50 | 19.39 | 0.58% |